Fungos liquenizados da Mata Atlântica, no sul do Brasil Lichenized fungi in the Atlantic Rainforest biome, in Southern Brazil

São apresentados resultados de levantamento baseado em dados de coletas de fungos liquenizados em algumas localidades de Mata Atlântica na região sul do Brasil. Foram identificados 88 táxons distribuídos em 18 famílias e 36 gêneros; destes, dois são citações novas para o Brasil e um é nova ocorrência para o Rio Grande do Sul.<br>The results of a survey based on data of lichenized fungi collections from some localities in the Atlantic Rainforest of South Brazil are presented. A total of 88 taxa distributed in 18 families and 36 genera were identified; from these, two are new records for Brazil and one is a new occurrence for the State of Rio Grande do Sul

Alginate: Pharmaceutical and Medical Applications

Due to their outstanding properties in terms of mild gelation conditions and simple functionalization, biocompatibility, low toxicity, biodegradability, non-antigenicity and chelating ability, as well as relatively low cost, alginates have been widely used in a variety of biomedical applications including tissue engineering and drug delivery systems. Smart alginate hydrogels for on-demand drug release in response to environmental stimuli and 3D bioprinting will play an important role in the future. These and the introduction of appropriate cell interactive features will be crucial for many tissue engineering applications. The focus of the present chapter is to highlight the great potential of the alginates as biomaterial for biomedical applications and to discuss the role that alginate-based materials are likely to play in biomedical applications in the future.info:eu-repo/semantics/publishedVersio

Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study

Background: While acute kidney injury (AKI) is a common complication in COVID-19, data on post-AKI kidney function recovery and the clinical factors associated with poor kidney function recovery is lacking. Methods: A retrospective multi-centre observational cohort study comprising 12,891 hospitalized patients aged 18 years or older with a diagnosis of SARS-CoV-2 infection confirmed by polymerase chain reaction from 1 January 2020 to 10 September 2020, and with at least one serum creatinine value 1–365 days prior to admission. Mortality and serum creatinine values were obtained up to 10 September 2021. Findings: Advanced age (HR 2.77, 95%CI 2.53–3.04, p < 0.0001), severe COVID-19 (HR 2.91, 95%CI 2.03–4.17, p < 0.0001), severe AKI (KDIGO stage 3: HR 4.22, 95%CI 3.55–5.00, p < 0.0001), and ischemic heart disease (HR 1.26, 95%CI 1.14–1.39, p < 0.0001) were associated with worse mortality outcomes. AKI severity (KDIGO stage 3: HR 0.41, 95%CI 0.37–0.46, p < 0.0001) was associated with worse kidney function recovery, whereas remdesivir use (HR 1.34, 95%CI 1.17–1.54, p < 0.0001) was associated with better kidney function recovery. In a subset of patients without chronic kidney disease, advanced age (HR 1.38, 95%CI 1.20–1.58, p < 0.0001), male sex (HR 1.67, 95%CI 1.45–1.93, p < 0.0001), severe AKI (KDIGO stage 3: HR 11.68, 95%CI 9.80–13.91, p < 0.0001), and hypertension (HR 1.22, 95%CI 1.10–1.36, p = 0.0002) were associated with post-AKI kidney function impairment. Furthermore, patients with COVID-19-associated AKI had significant and persistent elevations of baseline serum creatinine 125% or more at 180 days (RR 1.49, 95%CI 1.32–1.67) and 365 days (RR 1.54, 95%CI 1.21–1.96) compared to COVID-19 patients with no AKI. Interpretation: COVID-19-associated AKI was associated with higher mortality, and severe COVID-19-associated AKI was associated with worse long-term post-AKI kidney function recovery. Funding: Authors are supported by various funders, with full details stated in the acknowledgement section